Last reviewed · How we verify
NCT02985658
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
trial testing Veliparib in Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation. No longer available.
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- Veliparib — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
- Vinorelbine (vinorelbine) — full drug profile →
Conditions studied
- Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation — all drugs for Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation →
- Triple-Negative Breast Cancer — all drugs for Triple-Negative Breast Cancer →
Sponsor
University of Washington
Who can join
18 and older, female only, with Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation or Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02985658
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Veliparib
Trials testing the same drug.
- NCT03581292 — Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27 · Phase 2 · active not recruiting
- NCT03289910 — Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and · Phase 2 · active not recruiting
- NCT03032614 — Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients · Phase 2 · withdrawn
- NCT02631733 — Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors · Phase 1 · completed
- NCT03061188 — Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma · Phase 1 · completed
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02985658 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 21 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02985658.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing